Diagnosis and management of post-transplant lymphoproliferative disease following solid organ transplantation in children, adolescents, and young adults

Jeremy Rubinstein; Keri Toner; Thomas Gross; Birte Wistinghausen

doi:10.1016/j.beha.2023.101446

Diagnosis and management of post-transplant lymphoproliferative disease following solid organ transplantation in children, adolescents, and young adults

Jeremy Rubinstein
, Keri Toner
, Thomas Gross
, Birte Wistinghausen

Research output: Contribution to journal › Review article › peer-review

19 Scopus citations

Abstract

Post-transplant Lymphoproliferative Disease (PTLD) remains a major complication of solid organ transplantation (SOT) in pediatric patients. The majority are Epstein-Barr Virus (EBV) driven CD20⁺ B-cell proliferations responsive to reduction to immunosuppression and anti-CD20 directed immunotherapy. This review focusses on the epidemiology, role of EBV, clinical presentation, current treatment strategies, adoptive immunotherapy and future research in EBV + PTLD in pediatric patients.

Original language	English
Article number	101446
Journal	Best Practice and Research: Clinical Haematology
Volume	36
Issue number	1
DOIs	https://doi.org/10.1016/j.beha.2023.101446
State	Published - Mar 2023
Externally published	Yes

Keywords

Adoptive immunotherapy
EBV-Specific T-cell therapy
Epstein-Barr virus
Post-transplant lymphoproliferative disease
Solid organ transplantation

Access to Document

10.1016/j.beha.2023.101446

Cite this

@article{35397d314e314195b4f29812b8b859bd,

title = "Diagnosis and management of post-transplant lymphoproliferative disease following solid organ transplantation in children, adolescents, and young adults",

abstract = "Post-transplant Lymphoproliferative Disease (PTLD) remains a major complication of solid organ transplantation (SOT) in pediatric patients. The majority are Epstein-Barr Virus (EBV) driven CD20+ B-cell proliferations responsive to reduction to immunosuppression and anti-CD20 directed immunotherapy. This review focusses on the epidemiology, role of EBV, clinical presentation, current treatment strategies, adoptive immunotherapy and future research in EBV + PTLD in pediatric patients.",

keywords = "Adoptive immunotherapy, EBV-Specific T-cell therapy, Epstein-Barr virus, Post-transplant lymphoproliferative disease, Solid organ transplantation",

author = "Jeremy Rubinstein and Keri Toner and Thomas Gross and Birte Wistinghausen",

note = "Publisher Copyright: {\textcopyright} 2023",

year = "2023",

month = mar,

doi = "10.1016/j.beha.2023.101446",

language = "English",

volume = "36",

journal = "Best Practice and Research: Clinical Haematology",

issn = "1521-6926",

publisher = "Bailliere Tindall Ltd",

number = "1",

}

Diagnosis and management of post-transplant lymphoproliferative disease following solid organ transplantation in children, adolescents, and young adults. / Rubinstein, Jeremy; Toner, Keri; Gross, Thomas et al.
In: Best Practice and Research: Clinical Haematology, Vol. 36, No. 1, 101446, 03.2023.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - Diagnosis and management of post-transplant lymphoproliferative disease following solid organ transplantation in children, adolescents, and young adults

AU - Rubinstein, Jeremy

AU - Toner, Keri

AU - Gross, Thomas

AU - Wistinghausen, Birte

PY - 2023/3

Y1 - 2023/3

N2 - Post-transplant Lymphoproliferative Disease (PTLD) remains a major complication of solid organ transplantation (SOT) in pediatric patients. The majority are Epstein-Barr Virus (EBV) driven CD20+ B-cell proliferations responsive to reduction to immunosuppression and anti-CD20 directed immunotherapy. This review focusses on the epidemiology, role of EBV, clinical presentation, current treatment strategies, adoptive immunotherapy and future research in EBV + PTLD in pediatric patients.

AB - Post-transplant Lymphoproliferative Disease (PTLD) remains a major complication of solid organ transplantation (SOT) in pediatric patients. The majority are Epstein-Barr Virus (EBV) driven CD20+ B-cell proliferations responsive to reduction to immunosuppression and anti-CD20 directed immunotherapy. This review focusses on the epidemiology, role of EBV, clinical presentation, current treatment strategies, adoptive immunotherapy and future research in EBV + PTLD in pediatric patients.

KW - Adoptive immunotherapy

KW - EBV-Specific T-cell therapy

KW - Epstein-Barr virus

KW - Post-transplant lymphoproliferative disease

KW - Solid organ transplantation

UR - https://www.scopus.com/pages/publications/85148770984

U2 - 10.1016/j.beha.2023.101446

DO - 10.1016/j.beha.2023.101446

M3 - Review article

AN - SCOPUS:85148770984

SN - 1521-6926

VL - 36

JO - Best Practice and Research: Clinical Haematology

JF - Best Practice and Research: Clinical Haematology

IS - 1

M1 - 101446

ER -

Diagnosis and management of post-transplant lymphoproliferative disease following solid organ transplantation in children, adolescents, and young adults

Abstract

Keywords

Access to Document

Fingerprint

Cite this